Parents who gain access to usage logs can see just how much time their children spend inside YouTube's recommendation engine ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included ...

Greetings, and welcome to the Microsoft Fiscal Year 2026 Third Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to ...

Q1 2026 Earnings Call April 28, 2026 4:30 PM EDTCompany ParticipantsJames Todd - VP, Principal Accounting Officer ...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first ...

Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial ...

NR3C1 encodes the glucocorticoid receptor (GR) and regulates stress responses, metabolism, immune function, and inflammation, ...

Detailed price information for Generac Holdings Inc (GNRC-N) from The Globe and Mail including charting and trades.

A 12-year-old athlete prescribed a statin sparked a deeper question: are we treating numbers or people? This letter unpacks ...

Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% del ...